We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Immunoassay Detects Antibodies to American Trypanosomiasis

By LabMedica International staff writers
Posted on 11 Jan 2011
A fully automated immunoassay can determine the presence of antibodies to Trypanosoma cruzi, the causative agent of Chagas disease, in human serum and plasma.

The quantitative two-step chemiluminescent microparticle immunoassay (CMIA) has been compared to an enzyme linked immunoassays (ELISA) for specificity and sensitivity. More...
In the first step, sample, assay diluent, and paramagnetic microparticles co-coated with four chimeric T. cruzi recombinant antigens, are combined. A murine acridinium-labeled antihuman immunoglobulin (IgG) conjugate is added. After another wash cycle, pre-trigger and trigger solutions are added to the reaction mixture.

The ARCHITECT Chagas prototype assay (Abbott GmbH & Co.; Wiesbaden-Delkenheim, Germany) was tested on total of 10, 284 specimens to determine the specificity and sensitivity of the assay. The tests were done in Abbott's laboratory in Germany and in external sites in Guatemala and Brazil.

Of 10,284 specimens tested, 9,629 had a final interpretation of T. cruzi antibody-negative based on the testing algorithm used, whereas 655 specimens were determined to be T. cruzi antibody-positive. In comparison with the ELISA cruzi assay (bioMérieux; Marcy l'Etoile, France; www.biomerieux.com), the ARCHITECT assay demonstrated superior specificity (99.99% vs. 99.93%) and sensitivity (99.85% vs. 98.38%), along with excellent precision. This suggests that this CMIA has the potential to serve as single assay to determine the T. cruzi status of a given blood unit or diagnostic specimen on a fully automated instrument platform.

The authors of the study concluded that the utility of the fully automated ARCHITECT Chagas assay can be used in the diagnostic setting and for blood donor testing in endemic as well as nonendemic regions. The assay, once it is commercially available, might be used as a single test for routine testing in high-prevalence areas such as South and Central America, which would enable an economic testing strategy being highly advantageous for the target countries. Chagas disease or American Trypanosomiasis represents the third largest tropical disease burden worldwide, after malaria and schistosomiasis. The study was published in January 2011, in Diagnostic Microbiology and Infectious Disease.

Related Links:
bioMérieux
Abbott









New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Alcohol Testing Device
Dräger Alcotest 7000
New
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.